Q1 2025 Earnings Presentation FORWARD-LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements Disclosure. Certain information in this presentation contains "forward-looking" statements. You should not place undue reliance on these statements. Forward-looking statements include information concerning our possible or assumed future results of operations, including descriptions of our business strategies. These statements often include words such as "believe", "expect", "approximately", "an ...

Exhibit 99.1 For the three months ended March 31, 2025, from continuing operations: DURHAM, N.C., May 12, 2025— Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2025. "Fortrea's first quarter performance represents a solid start to 2025," said Tom Pike, Chairman and CEO of Fortrea. "We are focused on the disciplined execution of our strategy, strengthening our business model to improve our ef ...

Peter M. Neupert, Fortrea’s Lead Independent Director, will serve as Interim CEO as Thomas Pike steps downDURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that Thomas Pike is stepping down from his role as Fortrea’s Chief Executive Officer and as Chairman of its Board. Fortrea’s Lead Independent Director, Peter M. Neupert, will serve as Interim Chief Executive Officer and Board Chair, beginning May 1 ...

Company Overview - Fortrea Holdings Inc. (FTRE) is expected to report a year-over-year decline in earnings, with a projected loss of $0.08 per share, indicating a -100% change compared to the previous year [3] - Revenues for the upcoming quarter are anticipated to be $610.37 million, reflecting a decrease of 7.8% from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 28.64% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Fortrea Holdings is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +113.10% [10][11] Historical Performance - Fortrea Holdings has not been able to beat consensus EPS estimates in any of the last four quarters, with a notable surprise of -50% in the last reported quarter [12][13] Market Sentiment - The stock may experience upward movement if the actual results exceed expectations in the upcoming earnings report scheduled for May 12 [2] - Conversely, if the results fall short, the stock may decline [2] Industry Comparison - In the Zacks Medical - Biomedical and Genetics industry, Acadia Pharmaceuticals (ACAD) is expected to post earnings of $0.06 per share, representing a -40% year-over-year change, with revenues projected at $241.74 million, up 17.5% from the previous year [17] - Acadia's consensus EPS estimate has been revised down by 0.8% over the last 30 days, but it has a positive Earnings ESP of 17.37%, suggesting a likelihood of beating the consensus EPS estimate [18]

Recognized in both pre-and post-approval pharmacovigilance operationsDURHAM, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced it has been recognized as a “Leader” for pharmacovigilance (PV) operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix® Assessment 2025. Fortrea’s top position was recognized in both pre-and post-approval PV operations in Everest Group’s proprietary framework, which assess ...

Company Announcement - Fortrea will release its first quarter 2025 financial results on May 12, 2025, before the market opens [1] - A conference call will be held at 9:00 am ET on the same day to review the financial results and conduct a Q&A session [1] Participation Details - Participants can register for the earnings call online at the Fortrea Investor Relations website and are advised to join at least 10 minutes early to avoid delays [2] - A replay of the conference call will be available shortly after the event on the Fortrea Investor Relations website [2] Company Overview - Fortrea is a leading global provider of clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [3] - The company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [3] - Fortrea operates in about 100 countries, providing focused and agile solutions to its customers globally [3]

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fortrea Holdings Inc. (NASDAQ:FTRE) and Ibotta, Inc. (NYSE:IBTA). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided. Fortrea Holdings Inc. (NASDAQ:FTRE) On March 3, 2025, For ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ:FTRE) on behalf of Fortrea stockholders. Our investigation concerns whether Fortrea has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On March 3, 2025, Fortrea announced its fourth quarter and full y ...

"Price is what you pay, value is what you get"If you like my investment approach, you can buy my book ("The Most Boring Stock Investment Book") or join my newsletter ("Beating The Tide").Here is my free unsolicited advice:1. Save 10% of whatever you make, no matter how insignificant it can be. As a young engineer, I saved 10% of my income no matter if it was $10 or $1,000. PAYING YOURSELF is the best piece of advice you can give anyone. I recommend the book 'The Richest Man in Babylon', it is a bit repetiti ...

Core Insights - Kirby McInerney LLP is investigating potential claims against Fortrea Holdings Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3] Financial Performance - On March 3, 2025, Fortrea reported its fourth quarter and full year 2024 financial results, indicating that projects from before its spinoff from LabCorp are "late in their life cycle" with lower revenue and profitability than expected for 2025 [3] - The company stated that "post-spin work is not coming on fast enough to offset the pre-spin contract economics," leading to a negative impact on financial performance throughout 2025 [3] - Following the announcement, Fortrea's share price fell by $3.74, approximately 25%, from $13.85 on February 28, 2025, to $10.38 on March 3, 2025 [3]